A share price of Ovid Therapeutics Inc [OVID] is currently trading at $0.74, up 1.85%. An important factor to consider is whether the stock is rising or falling in short-term value. The OVID shares have gain 5.46% over the last week, with a monthly amount drifted -25.72%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on June 18, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, B. Riley Securities started tracking the stock with Buy rating on April 30, 2024, and set its price target to $9. On April 29, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on April 05, 2024. BTIG Research initiated its recommendation with a Buy and recommended $11 as its price target on December 21, 2023. Oppenheimer started tracking with a Outperform rating for this stock on October 13, 2023, and assigned it a price target of $8. In a note dated April 20, 2021, Cantor Fitzgerald downgraded an Neutral rating on this stock but restated the target price of $4.
Ovid Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.68 and $4.10. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $0.74 at the most recent close of the market. An investor can expect a potential return of 890.54% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Trailing Twelve Months sales for Ovid Therapeutics Inc [NASDAQ:OVID] were 0.63M which represents 58.76% growth. Gross Profit Margin for this corporation currently stands at -0.09% with Operating Profit Margin at -109.8%, Pretax Profit Margin comes in at -51.46%, and Net Profit Margin reading is -51.46%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.39 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6986 points at the first support level, and at 0.6557 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7961, and for the 2nd resistance point, it is at 0.8507.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ovid Therapeutics Inc [NASDAQ:OVID] is 5.66. On the other hand, the Quick Ratio is 5.66, and the Cash Ratio is 1.29. Considering the valuation of this stock, the price to sales ratio is 83.57, the price to book ratio is 0.69.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Jan 27 ’25 when 6810.0 shares were purchased. CEO, LEVIN JEREMY M completed a deal on Mar 18 ’24 to buy 18248.0 shares.
